Ovarian cancer has the highest mortality rate among gynecological tumors. Although complete response（CR）can be achieved in most patients after initial treatment，its prognosis is often poor because of its critical prognostic factor，platinum⁃free interval（PFI）and its relapse within five years still happens in more than half of the affected patients. So far there is no effective treatment for the patients. The main treatment regimen for patients with platinum ⁃ resistant ovarian cancer is currently single ⁃ drug chemotherapy，which is comprehensively practiced clinically as a standard therapy. Meanwhile，an increasing number of studies show that immunotherapy can improve the prognosis of patients with a variety of solid tumors. Here，we reviewed the current evidence for the use of immunotherapy in the treatment of platinum⁃resistant ovarian cancer so as to provide new clues and basis for its clinical treatment.